AA Signature provides an innovative approach to treatment planning that focuses on patient outcomes
Recommendation based on results of Phase 3 CheckMate -9DW clinical trial demonstrating statistically significant and clinically meaningful improvement in overall survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib in this patient population
The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022, is now also approved to aid in the assessment of HER2-ultralow status for metastatic breast cancer patients.
The group reported Q3FY25 operating revenue of Rs 3,821 crore, driven by sustained double-digit growth of 14 per cent in biosimilars
The 33% year-over-year revenue growth and a remarkable 45% surge in gross profit reflect our strong market presence and efficient execution across therapeutic segments
Torrent Pharmaceuticals has reported total income of Rs. 2,842 crores during the period ended December 31, 2024
RPG Life Sciences has reported total income of Rs. 176.02 crore during the period ended December 31, 2024
Laurus Labs has reported total income of Rs. 1,424.47 crores during the period ended December 31, 2024
The company said it voluntarily paused production at the Gagillapur plant in September 2024 for risk assessment on account of the USFDA observations
Q3 FY25 revenue up 24% to Rs 3,230 crore
Subscribe To Our Newsletter & Stay Updated
